The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | How bispecific antibodies contribute to T-cell activation in AML
In this video, Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, highlights some findings presented at this year’s ASH meeting, where researchers investigated how T-cells and acute myeloid leukemia (AML) cells communicate, and how bispecific antibodies contribute to the formation of a strong immunological synapse. Dr Subklewe explains how conventional bispecifics using only CD3 engagement are less efficient at eliciting a response, and that adding a positive co-stimulatory molecule can result in stronger activation of T-cells. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
